What is GYRE's P/E ratio?

Gyre Therapeutics Inc. (GYRE) currently trades at a P/E ratio of 168.11.

Gyre Therapeutics Inc. reports a Return on Equity (ROE) of -6.21%.

What is GYRE's dividend yield?

Gyre Therapeutics Inc. offers a dividend yield of 0.00%.

What is GYRE's Quality Score?

Our AI rates GYRE's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy GYRE?

Our AI Timing Score for GYRE is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does GYRE belong to?

Gyre Therapeutics Inc. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Gyre Therapeutics Inc. (GYRE) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

GYRE AI Analysis Summary

Our AI summary for GYRE: Gyre Therapeutics Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 168.11, ROE of -6.21%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

GYRE

Gyre Therapeutics Inc.

US:NASDAQ STOCK Healthcare >> Biotechnology News 97

USD 6.15

0.04 (0.65%) Day Change

Watchlist Portfolio Compare Chart

168.11

P/E

0.01

D/E

-6.2%

ROE

-3.9%

ROA

0.00%

Div Yield

-0.10

PEG

GYRE THERAPEUTICS INC.
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 6.15 Price 0.04 (0.65%) Day Change	NEWS SCORE: 97

GYRE, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...

Loading chart...

15 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not quite good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

50%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	97
Magic Formula Rank by ROA	2798
Magic Formula Rank by ROE	2798
Magic Formula Rank by ROIC	2166
Price	6.15
PBV / Sector	4.97 / 44,022.72
Earning Per Share	-0.06

PE / Sector	168.11 / 19.17
PEG or PE/Growth / Sector	-0.10 / 1.24
Average 1M Daily Value	0.35 M GREAT
Average 1W Daily Value	0.32 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-5.37 / 98.24
NPM Average (%) / Sector	-13.86 / -1,697.63
NPM Change Average (%) / Sector	-1,035.18 / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-3.88 / 185,260.96
ROA Average (%) / Sector	-13.65 / 36,684.70
ROA Change Average (%) / Sector	-861.22 / 422,221.66
ROE (%) / Sector	-6.21 / 243,762.23
ROE Average (%) / Sector	122.04 / 48,758.47 GREAT
ROE Change Average (%) / Sector	2,585.69 / 424,968.10 GOOD
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

41%

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	224.93 / 17.04 GREAT
Dividend Change Average (%) / Sector	-96.78 / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:18
Symbol	GYRE
Name	GYRE THERAPEUTICS INC.
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	111.49 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	681.20 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 12730 High Bluff Drive, San Diego, CA, United States, 92130

Phone: 858-284-0115

Website: https://www.gyretx.com

Employees: 625

Sector: Healthcare >> Biotechnology

Description: Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.